502788986 04/30/2014

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2835581

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
LONZA BIOLOGICS INC.	05/10/2012

RECEIVING PARTY DATA

Name:	ALEXION PHARMACEUTICALS, INC.
Street Address:	352 KNOTTER DRIVE
City:	CHESHIRE
State/Country:	CONNECTICUT
Postal Code:	06410

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14000055

CORRESPONDENCE DATA

Fax Number: (877)769-7945

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via

US Mail.

Phone: 612-335-5070 **Email:** wasilkus@fr.com

Correspondent Name: FISH & RICHARDSON P.C. Address Line 1: 60 SOUTH SIXTH STREET

Address Line 2: 3200 RBC PLAZA

Address Line 4: MINNEAPOLIS, MINNESOTA 55402

ATTORNEY DOCKET NUMBER:	37460-0004US1	
NAME OF SUBMITTER:	ANGELA D. FOLLETT, PH.D., REG. NO. 60365	
SIGNATURE:	/Angela D. Follett, Ph.D./	
DATE SIGNED:	04/30/2014	

Total Attachments: 2

source=Lonza_AlexionPharm#page1.tif source=Lonza_AlexionPharm#page2.tif

PATENT 502788986 REEL: 032787 FRAME: 0520

Attorney Docket No.: 29910-0004F63

ASSIGNMENT

WHEREAS, Lonza Biologics Inc. (hereinafter termed "Assignor"), a Delaware Corporation, having a place of business at 101 International Drive. Portsmouth. New Hampshire 03801, owns the entire right, title, and interest of the Lonza Biologics Inc. inventors Xiangtian Long, Danmei Dai, and Andreas Brunner in the inventions described below (hereinafter "Said Inventions"),

METHOD FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES

naming as inventors <u>Xiangtian Long</u> of <u>Room 2-2-302</u>, <u>Gezhi Garden, Sun Yat-sen University</u>, <u>Guangzhou Higher Education Mega Center</u>, <u>Guangzhou 510006</u>, <u>China</u>; <u>Danmei Dai of Room A1905</u>, <u>Building 19</u>, <u>Dongfang 3 Lu, Tianhe District</u>, <u>Guangzhou 510630</u>, <u>China</u>; and <u>Andreas Brunner of Metzgergasse 2</u>, <u>Brig CH-3900</u>, <u>Switzerland</u>, together with Derek Kevin Watt, Keith Clinch, Rachel Anne Dixon, Sylvia Myrna Baars, Nicolas Georges Rene Proisy, Cyrille Abel Sébastien Landreau, and Gillian Mary Little, for which U.S. Provisional Patent Application Serial Number <u>61/599,314</u> was filed on <u>February 15, 2012</u>, and said Assignor authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting above the filing date and serial number of said application when known, and

WHEREAS, Alexion Pharmaceuticals, Inc. (hereinafter termed "Assignee"), a corporation organized and existing under the laws of the state of Delaware, having a principle place of business at 352 Knotter Drive, Cheshire, Connecticut 06410, desires to acquire said Assignor's entire right, title, and interest in and to Said Inventions, and in and to any and all patent applications, patents, inventor's certificates, and other forms of protection thereon granted in the United States and foreign countries, the desired acquisition in accordance with agreements duly entered into with said Assignor;

NOW, THEREFORE, in consideration of said agreements and of good and valuable consideration acknowledged by said Assignor to have been received from said Assignee:

1. Said Assignor has sold, assigned, transferred, and conveyed, and by these presents does hereby sell, assign, transfer, and convey, unto said Assignee the entire right, title, and interest: (a) in Said Inventions; (b) in and to all rights to apply for foreign patents on Said Inventions pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on Said Inventions in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said applications; and (d) in and to each and every reissue or extension of any of said patents.

Assignment Page 1 of 2

- Assignee to enable said Assignee to enjoy to the fullest extent the right, title, and interest herein conveyed in the United States and foreign countries. Such cooperation by said Assigner shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations, or other papers, and other assistance all to the extent deemed reasonably necessary or desirable by the parties: (a) for perfecting in said Assignee the right, title, and interest herein conveyed; (b) for prosecuting any of said applications relating to Said Inventions; (c) for filing and prosecuting substitute, divisional, continuing, or additional applications covering Said Inventions; (d) for filing and prosecuting applications for reissuance of any of said patents relating to Said Inventions; (e) for interference or other priority proceedings involving Said Inventions; and (f) for legal proceedings involving Said Inventions and any applications therefore and any patents granted thereon, including, without limitation, reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions, and any court actions.
- 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns, and other legal representatives, and shall be binding upon the Assignor, its successors, assigns, and other legal representatives.
- 4. Said Assignor hereby warrants and represents that the Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee this 18 45 day of 19 2012.

LONZA BIOLOGICS INC.	ALEXION PHARMACEUTICALS, INC
By: 14/1/4/	Ву:
Scott B. Waldman Title: U.S. General Counsel,	Title:
Vice President and Secretary	

